PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 176 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,421,422 | -24.5% | 1,681,149 | +1.4% | 0.37% | -23.5% |
Q2 2023 | $5,853,428 | -2.3% | 1,658,195 | -14.4% | 0.49% | +17.0% |
Q1 2023 | $5,988,692 | -6.1% | 1,938,088 | +28.5% | 0.42% | -25.1% |
Q4 2022 | $6,377,414 | +78.7% | 1,507,663 | +0.1% | 0.56% | +80.6% |
Q3 2022 | $3,568,521 | -12.7% | 1,505,705 | +4.9% | 0.31% | +6.2% |
Q2 2022 | $4,089,969 | -0.3% | 1,435,077 | +0.7% | 0.29% | -7.6% |
Q1 2022 | $4,102,992 | +20.7% | 1,424,650 | +27.4% | 0.32% | +45.2% |
Q4 2021 | $3,398,410 | +21.8% | 1,117,898 | +180.9% | 0.22% | +11.9% |
Q3 2021 | $2,789,559 | +467.4% | 397,940 | +583.1% | 0.19% | +59.0% |
Q1 2020 | $491,638 | -42.9% | 58,251 | +37.7% | 0.12% | -73.8% |
Q4 2018 | $860,825 | -13.4% | 42,301 | +95.2% | 0.47% | +6.9% |
Q3 2018 | $993,615 | -29.8% | 21,671 | -9.4% | 0.44% | -32.6% |
Q2 2018 | $1,415,105 | -9.3% | 23,924 | +4.4% | 0.65% | -10.8% |
Q1 2018 | $1,559,978 | -71.1% | 22,924 | -58.1% | 0.72% | -76.7% |
Q4 2017 | $5,402,054 | – | 54,649 | – | 3.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 200,000 | $20,706,000 | 6.01% |
Redmile Group, LLC | 230,673 | $23,882,000 | 2.95% |
WEATHERBIE CAPITAL, LLC | 241,419 | $24,994,000 | 2.31% |
Tekla Capital Management LLC | 185,820 | $19,238,000 | 2.02% |
Ghost Tree Capital, LLC | 25,000 | $2,588,000 | 1.59% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $588,741,000 | 1.56% |
Iguana Healthcare Management, LLC | 25,000 | $2,588,000 | 1.48% |
Eventide Asset Management | 42,100 | $4,359,000 | 1.34% |
Bain Capital Public Equity Management, LLC | 401,330 | $41,550,000 | 1.17% |
Rock Springs Capital Management LP | 31,500 | $3,261,000 | 1.16% |